Initial Workup for Irregular Menses (Oligomenorrhea or Amenorrhea)

Definition and Classification

• Oligomenorrhea is defined as menstrual cycles occurring at intervals greater than 35 days 1
• Secondary amenorrhea is classified as cessation of previously regular menses for 3 months or previously irregular menses for 6 months 1

Initial Clinical Assessment

• A detailed menstrual history, including age of menarche, regularity of cycles, and duration of irregularity, should be taken 1
• Medical history, including weight changes, eating patterns, and exercise habits, should be assessed 2
• Medication use, including hormonal contraceptives, should be documented 1
• Symptoms suggesting specific etiologies, such as galactorrhea, should be evaluated 1
• BMI calculation is essential, as obesity is associated with PCOS and menstrual irregularities 3

Laboratory Testing

• Pregnancy test should be performed to exclude pregnancy as a cause of amenorrhea 1
• Hormonal assessment, including FSH, LH, TSH, prolactin, and estradiol levels, should be conducted 1, 4
• LH/FSH ratio >2 suggests PCOS 1

Imaging Studies

• Pelvic ultrasonography is indicated when clinical features or hormonal tests suggest ovarian pathology 1
• Transvaginal ultrasound is more sensitive than transabdominal for identifying structural abnormalities 1
• Endometrial thickness should be assessed 5, 6

Common Pitfalls and Considerations

• Patients with amenorrhea due to hypothalamic causes should be evaluated for disordered eating and low bone density 2
• Certain medications, including antipsychotics, antiepileptics, and hormonal contraceptives, can cause irregular menses 7

Evaluation and Management of Oligomenorrhea

Initial Assessment

• Assessment of weight changes, eating patterns, and exercise habits to evaluate for Female Athlete Triad or disordered eating is crucial in patients with oligomenorrhea, as recommended by the American College of Sports Medicine 8, 9
• Thyroid examination to identify enlargement or nodules is an essential part of the physical examination, as suggested by the Centers for Disease Control and Prevention 10
• Breast and pubic hair development (Tanner staging) should be evaluated, as recommended by the American Society of Clinical Oncology 11

Laboratory Testing and Referral

• Pregnancy test is necessary to exclude pregnancy as a cause of oligomenorrhea, as recommended by the Centers for Disease Control and Prevention 10
• Referral to a specialist is recommended if laboratory testing reveals significant abnormalities, or if there is concern for an eating disorder or Female Athlete Triad, as suggested by the American Society of Clinical Oncology 12, 13
• The American College of Sports Medicine recommends evaluating for disordered eating or excessive exercise in thin or athletic patients with oligomenorrhea 8, 9

Progesterone Testing for Irregular Menstrual Periods

Indications and Interpretation

• The American College of Obstetricians and Gynecologists recommends that pregnancy be ruled out before other hormonal testing, with a pregnancy test being performed first to exclude pregnancy as a cause of amenorrhea or irregular bleeding 14
• The Endocrine Society suggests that to differentiate between polycystic ovarian syndrome (PCOS) and functional hypothalamic amenorrhea (FHA), progesterone testing can be used, with low progesterone levels (<5 ng/mL) throughout the cycle suggesting anovulation, which may be due to PCOS or FHA 15
• The American Society for Reproductive Medicine indicates that premature ovarian failure is associated with elevated FSH, and progesterone levels can help in the differential diagnosis 16
• The Centers for Disease Control and Prevention recommends that pregnancy be ruled out before other hormonal testing, and failing to do so can lead to misinterpretation of hormonal results 14, 17

Additional Testing and Treatment

• The Endocrine Society recommends that estradiol level be checked, with low levels suggesting hypoestrogenism as in FHA, and a progesterone challenge test may be considered to assess estrogen status and endometrial response 15

Diagnostic Approach to Amenorrhea

Initial Evaluation and Laboratory Testing

• The American College of Obstetricians and Gynecologists recommends assessing endometrial thickness via ultrasound, with thin endometrium (<5 mm) suggesting estrogen deficiency and thick endometrium (>8 mm) suggesting chronic anovulation with unopposed estrogen 18
• A progesterone challenge test can differentiate PCOS (positive withdrawal bleed) from functional hypothalamic amenorrhea (negative), though endometrial thickness on ultrasound is more reliable 18

Diagnostic Algorithm by FSH Level

• Elevated FSH (>40 mIU/mL) confirms primary ovarian insufficiency, which should be confirmed with repeat FSH 4 weeks later (two elevated values required for diagnosis) 19, 20, 21

Special Considerations

• Patients with primary ovarian insufficiency can maintain unpredictable ovarian function and should not be presumed infertile, with the American Society for Reproductive Medicine recommending karyotype testing if age <40 years to identify Turner syndrome or premature ovarian insufficiency 19, 20, 21

Laboratory Evaluation for Amenorrhea

Initial Mandatory Laboratory Tests

• The American College of Obstetricians and Gynecologists recommends measuring luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels to identify primary ovarian insufficiency and polycystic ovary syndrome (PCOS), with an LH/FSH ratio >2 suggesting PCOS 22
• The Endocrine Society suggests measuring thyroid-stimulating hormone (TSH) levels to identify thyroid dysfunction as a reversible cause of amenorrhea, with elevated levels indicating hypothyroidism or hyperthyroidism 23
• The American College of Obstetricians and Gynecologists recommends measuring prolactin levels, with elevated levels (>20 μg/L) suggesting hyperprolactinemia, which may indicate a pituitary adenoma or medication effect 23

Additional Hormonal Testing Based on Clinical Context

• The American Society for Reproductive Medicine recommends measuring estradiol levels when functional hypothalamic amenorrhea (FHA) is suspected, with low levels indicating hypoestrogenism 23
• The Endocrine Society suggests measuring progesterone levels (measured mid-luteal phase) to determine ovulatory status, with levels <6 nmol/L indicating anovulation, commonly seen in PCOS, hypothalamic amenorrhea, or hyperprolactinemia 22
• The American College of Obstetricians and Gynecologists recommends measuring testosterone and androstenedione levels when clinical signs of hyperandrogenism are present (hirsutism, acne), with testosterone >2.5 nmol/l suggesting PCOS or valproate use 22

Timing Considerations for Laboratory Testing

• The American College of Obstetricians and Gynecologists recommends drawing blood samples for FSH, LH, and testosterone between days 3-6 of the menstrual cycle (or at any time in amenorrheic patients) 22
• The Endocrine Society suggests drawing blood for progesterone assessment during the mid-luteal phase according to the menstrual cycle 22

Special Population Considerations

• The International Olympic Committee recommends evaluating female athletes for the Female Athlete Triad by documenting weight changes, eating patterns, and exercise habits, and obtaining bone mineral density testing via DXA in those with energy deficiency-related amenorrhea 24
• The National Comprehensive Cancer Network recommends measuring FSH and estradiol levels in cancer survivors, but hormone replacement therapy must be discontinued prior to laboratory evaluation, and anti-Müllerian hormone (AMH) and inhibin may provide additional information on ovarian status 23

Diagnostic Approach to Amenorrhea

Hormonal Evaluation

• The LH/FSH ratio >2 strongly suggests Polycystic Ovary Syndrome (PCOS), while a ratio <1 is seen in approximately 82% of functional hypothalamic amenorrhea (FHA) cases, according to the Human Reproduction Update 25
• Estradiol assessment helps differentiate FHA (low estradiol) from PCOS (normal/elevated estradiol), as reported in the Human Reproduction Update 25
• Misdiagnosing FHA with polycystic ovarian morphology (FHA-PCOM) as PCOS can occur, but FHA patients typically have low LH, low estradiol, thin endometrium (<5 mm), and LH/FSH ratio <1, despite ovarian appearance on ultrasound, as noted in the Human Reproduction Update 25

Special Considerations in Cancer Survivors

• For patients age ≤60 years with prior hysterectomy and intact ovaries, measure LH, FSH, and estradiol prior to initiating any systemic therapy to accurately assess menopausal status, as recommended by the Journal of Clinical Oncology 26
• Assuming chemotherapy-induced amenorrhea equals menopause can be incorrect, as hormone levels and absence of menses are unreliable indicators during tamoxifen treatment, and premenopausal estradiol levels can occur with transient chemotherapy-induced amenorrhea, according to the Journal of Clinical Oncology 26

Assessment of Hyperandrogenism in Oligomenorrhea

Clinical Indicators

• Evaluate for hyperandrogenic manifestations – signs such as hirsutism, acne, androgenetic alopecia, or truncal obesity should be documented because they may signal underlying polycystic ovary syndrome or other sources of excess androgen exposure. 27

Laboratory Evaluation

• Add adrenal and ovarian androgen testing – when hyperandrogenic signs are present, measurement of serum androstenedione and dehydroepiandrosterone sulfate (DHEA‑S) is advised to screen for adrenal or ovarian tumors and for non‑classical congenital adrenal hyperplasia. 27

Laboratory Evaluation Guidelines for Amenorrhea

Core Hormonal Panel

• Serum prolactin > 20 µg/L indicates hyperprolactinemia and should prompt evaluation for pituitary adenoma or medication effects. 28
• Thyroid‑stimulating hormone (TSH) testing identifies thyroid dysfunction, a reversible cause of amenorrhea; both hypothyroidism and hyperthyroidism can disrupt menstrual cycles. 28
• Follicle‑stimulating hormone (FSH) and luteinizing hormone (LH) should be drawn between cycle days 3‑6 when cycles are present (or at any time in amenorrheic patients); the LH/FSH ratio aids etiologic differentiation. 28

Interpretation of Hormone Ratios

• An LH/FSH ratio > 2 strongly suggests polycystic ovary syndrome (PCOS). 28

Additional Hormonal Testing Based on Clinical Context

• Total testosterone > 2.5 nmol/L (drawn on days 3‑6) supports a diagnosis of PCOS or indicates possible valproate effect. 28
• Androstenedione > 10.0 nmol/L warrants investigation for adrenal or ovarian neoplasms. 28
• Age‑adjusted DHEA‑S thresholds (age 20‑29 > 3800 ng/mL; age 30‑39 > 2700 ng/mL) screen for non‑classical congenital adrenal hyperplasia. 28
• Estradiol < 30 pg/mL confirms hypo‑estrogenism characteristic of functional hypothalamic amenorrhea (FHA). 29
• Mid‑luteal progesterone < 6 nmol/L indicates anovulation (relevant in PCOS, hypothalamic amenorrhea, or hyperprolactinemia). 28

Metabolic and Genetic Assessment

• Fasting glucose > 7.8 mmol/L suggests diabetes; a glucose/insulin ratio > 4 points to reduced insulin sensitivity associated with PCOS. 28
• Karyotype analysis is recommended for women < 40 years with elevated FSH to detect Turner syndrome or other chromosomal abnormalities. 29

Timing of Sample Collection

• FSH, LH, and testosterone should be drawn between cycle days 3‑6 (or any time in amenorrheic patients). 28
• Progesterone must be obtained during the expected mid‑luteal phase to assess ovulation. 28
• Prolactin sampling requires a single morning resting draw; it must never be performed post‑ictally because seizures cause transient elevation. 28

Clinical Triggers for Specific Tests

• Presence of galactorrhea mandates prolactin measurement and further evaluation for pituitary pathology. 28
• Body‑mass index > 25 kg/m² is associated with PCOS, whereas BMI < 18.5 kg/m² favors FHA. 28
• Waist‑to‑hip ratio > 0.9 suggests truncal obesity and supports a PCOS work‑up. 28
• A Ferriman‑Gallwey score indicating hirsutism warrants androgen testing (testosterone, androstenedione, DHEA‑S). 28

Common Pitfalls to Avoid

• Do not draw prolactin immediately after a seizure; wait at least 24 hours to avoid false‑positive elevations. 28

Prolactin and Testosterone Evaluation in Perimenopausal Women

Pitfalls in Hormone Measurement

• Avoid measuring prolactin immediately after stressors (e.g., recent stress, breast examination, or sexual activity) because these conditions can cause transient elevations; instead, obtain a morning resting sample to ensure accurate assessment. 30

Referral Thresholds for Specialist Evaluation

• Refer for endocrine or neurosurgical assessment when prolactin levels exceed 100 µg/L or any elevation is accompanied by headaches or visual disturbances, as these findings suggest a possible pituitary adenoma. 30

• Refer when total testosterone levels are greater than 5 nmol/L or when rapid virilization occurs, indicating a potential ovarian or adrenal tumor. 30

Unnecessary Initial Tests for Menstrual Irregularity in Healthy Adolescents

Routine Tests Not Recommended

• The CDC (MMWR Recommendations and Reports) advises that a pelvic examination is not required for the initial evaluation of menstrual irregularity in a healthy 18‑year‑old female, except when an intrauterine device is being placed or a diaphragm is being fitted. 31
• According to CDC guidance, routine cervical cytology (Pap smear) is unnecessary in the initial workup of menstrual irregularity for an 18‑year‑old woman without specific risk factors. 32
• The CDC recommends that a clinical breast examination should not be performed as part of the standard initial assessment of menstrual irregularity in a healthy 18‑year‑old female. 31
• CDC guidelines state that HIV screening is not indicated in the routine initial evaluation of menstrual irregularity for an 18‑year‑old woman unless there are additional risk considerations. 31
• The CDC (MMWR Recommendations and Reports) indicates that lipid panels, fasting glucose, and liver enzyme tests are not required in the basic workup of menstrual irregularity in a healthy 18‑year‑old female unless there is a specific clinical indication. 32